Details:
The strategic investment advances Immuron’s objective to enter the broader IBS market with leading products and strengthen the distribution of Immuron’s Travelan® products through B2C online platforms and pharmacy and retail channels in target markets.
Lead Product(s): Bovine Colostrum
Therapeutic Area: Gastroenterology Product Name: Travelan
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Immuron
Deal Size: Undisclosed Upfront Cash: $1.8 million
Deal Type: Financing November 16, 2022
Details:
The investment is made with the intention to enter into reciprocal distribution agreement for Travelan® (bovine colostrum) in the U.K. market and JUVIA™ in Australian and North American markets.
Lead Product(s): Bovine Colostrum
Therapeutic Area: Gastroenterology Product Name: Travelan
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Immuron
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 13, 2022
Details:
With the acquisition, addition of the two products expands the presence in acute care space, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection) join Eagle portfolio.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Eagle Pharmaceuticals
Deal Size: $182.4 million Upfront Cash: $78.5 million
Deal Type: Acquisition June 09, 2022
Details:
Opportunity for Eagle’s highly skilled hospital-based salesforce to integrate and promote BYFAVO and BARHEMSYS and to leverage longstanding relationships to realize the full potential of these assets.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Eagle Pharmaceuticals
Deal Size: $182.4 million Upfront Cash: $78.5 million
Deal Type: Acquisition March 28, 2022
Details:
Barhemsys® is an intravenous formulation of amisulpride, a selective dopamine antagonist. It is approved in the US for treatment and prophylaxis of PONV, alone and in combination with other antiemetics.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
The net proceeds of the Placing are intended to be used To meet its sales force and marketing costs relating to BARHEMSYS® and BYFAVO™ including brand development and engagement with key opinion leaders, healthcare professionals and medical conference and speaker programs.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $23.5 million Upfront Cash: Undisclosed
Deal Type: Financing February 18, 2021
Details:
The Company plans to deploy this capital to support its ongoing US launches of BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting and BYFAVO™ (remimazolam for injection) for procedural sedation.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing October 09, 2020
Details:
RedHill Biopharma has gained the rights to Movantik (naloxegol)1 in Israel from AstraZeneca. RedHill now holds the worldwide rights to Movantik, excluding Europe and Canada. RedHill to evaluate partnering opportunities for commercialization of Movantik in Israel.
Lead Product(s): Naloxegol Oxalate
Therapeutic Area: Gastroenterology Product Name: Moventig
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: RedHill Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 08, 2020
Details:
BARHEMSYS® (amisulpride injection) has been launched and is now commercially available in the US for order and delivery to customers through major wholesalers and specialty distributors.
Lead Product(s): Amisulpride
Therapeutic Area: Gastroenterology Product Name: Barhemsys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which has now been transferred to RedHill.
Lead Product(s): Naloxegol Oxalate
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: RedHill Biopharma
Deal Size: $67.5 million Upfront Cash: $52.5 million
Deal Type: Divestment April 02, 2020